Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Brain | Positive | Positive | (ADENOCARCINOMA, NEUROBLASTOMA, CARCINOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| Yes | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/50 2/48 1/49 | May Have Been Related |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Clear Evidence | (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50 | Neoplastic Lesions |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60 | May Have Been Related |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 4/50 4/50 | Neoplastic Lesions |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60 | May Have Been Related |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 5/50 6/50 | Neoplastic Lesions |
| Yes | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Male | Inhalation | Brain | Some Evidence | Equivocal Evidence | GRANULAR CELL TUMOR 0/49 3/50 1/50 1/50; GLIOMA 0/49 1/50 0/50 0/50, ASTROCYTOMA 0/49 1/50 0/50 0/50, OR OLIGODENDROGLIOMA 0/49 1/50 0/50 0/50 COMBINED 0/49 3/50 0/50 0/50 | May Have Been Related |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 1/35 1/65 2/50 | May Have Been Related |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 2/44 3/75 1/60 | May Have Been Related |
| Yes | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Female | Inhalation | Brain | Some Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 0/50 1/50 0/50, GLIOMA 0/50 0/50 0/50 1/50, MEDULOBLASTOMA 0/50 0/50 0/50 1/50, MENINGEAL GRANULAR CELL TUMOR 0/50 1/50 0/50 1/50, MENINGEAL SARCOMA 0/50 1/50 0/50 1/50 | May Have Been Related |
| Yes | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Brain | Clear Evidence | Equivocal Evidence | meninges, granular cell tumor benign or malignant (1/90, 3/90, 4/90, 3/90) | May Have Been Related |
| Yes | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Brain | Clear Evidence | Clear Evidence | glioma malignant (0/90, 3/90, 3/90, 2/90) | Neoplastic Lesions |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 3/50 1/50 | May Have Been Related |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 4/50 3/50 | May Have Been Related |
| Yes | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Brain | Clear Evidence | Clear Evidence | glioma malignant (0/90, 0/90, 0/90, 3/90) | Neoplastic Lesions |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/50 2/48 1/49 | May Have Been Related |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Clear Evidence | (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | PAPILLOMA 0/49 4/42 10/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | PAPILLOMA 0/49 5/40 0/44 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 1/50 10/49 10/49 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 0/50 23/50 29/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/47 4/49 OR CARCINOMA 0/50 1/47 1/49 COMBINED 0/50 2/47 5/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 9/48 20/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 6/48 8/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 12/49 11/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 2/49 5/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ACINAR CELL CARCINOMA 0/50 2/49 6/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Ovary | Clear Evidence | Clear Evidence | GRANULOSA CELL TUMOR 0/49 6/45 12/48 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Ovary | Clear Evidence | Clear Evidence | BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Preputial Gland | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL CARCINOMA 0/50 3/50 1/50 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Preputial Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Equivocal Evidence | NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80 | May Have Been Related |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 11/48 18/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 16/49 7/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | (STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50 | May Have Been Related |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 0/50 2/50 | May Have Been Related |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 2/44 3/75 1/60 | May Have Been Related |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/60 2/45 14/75 20/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 2/60 1/45 7/75 6/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60 | Neoplastic Lesions |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60 | May Have Been Related |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 2/45 7/75 4/60 OR ADENOCARCINOMA 0/60 0/45 3/75 6/60 COMBINED 0/60 2/45 10/75 9/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 7/75 10/60 OR ADENOCARCINOMA 0/60 0/45 3/75 15/60 COMBINED 0/60 0/45 10/75 23/75 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 7/74 3/60 OR CARCINOMA 0/60 0/45 1/74 1/60 COMBINED 0/60 0/45 7/74 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 29/75 26/60 OR CARCINOMA 0/60 0/45 12/75 12/60 COMBINED 0/60 0/45 35/75 33/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 1/45 3/74 3/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 0/74 1/60 COMBINED 1/60 1/45 3/74 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 0/45 7/75 6/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 1/75 0/60 COMBINED 1/60 0/45 8/75 6/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/60 1/45 3/75 6/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/60 0/45 3/75 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 3/45 7/75 9/60 OR SQUAMOUS CELL CARCINOMA 0/60 1/45 2/75 4/60 COMBINED 0/60 3/45 9/75 13/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 2/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 1/75 3/60 COMBINED 0/60 0/45 4/75 5/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 2/60 4/45 4/75 8/60 OR CARCINOMA 0/60 0/45 2/75 1/60 COMBINED 2/60 4/45 6/75 9/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 4/45 11/75 12/60 OR CARCINOMA 0/60 2/45 22/75 35/60 COMBINED 0/57 6/45 32/75 42/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 1/60 1/45 13/75 16/60 OR CARCINOMA 0/60 2/45 21/75 23/60 COMBINED 1/60 3/45 32/75 36/60 | Neoplastic Lesions |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Male | Inhalation | Adrenal Gland Medulla | Some Evidence | Some Evidence | PHEOCHROMOCYTOMA 8/48 23/47 17/50 21/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 2/50 0/49 COMBINED 8/48 23/47 18/50 21/49 | Neoplastic Lesions |
| Yes | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Male | Inhalation | Brain | Some Evidence | Equivocal Evidence | GRANULAR CELL TUMOR 0/49 3/50 1/50 1/50; GLIOMA 0/49 1/50 0/50 0/50, ASTROCYTOMA 0/49 1/50 0/50 0/50, OR OLIGODENDROGLIOMA 0/49 1/50 0/50 0/50 COMBINED 0/49 3/50 0/50 0/50 | May Have Been Related |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Female | Inhalation | Brain | Equivocal Evidence | Equivocal Evidence | GLIOMA 0/50 1/50 1/48 3/50 | Neoplastic Lesions |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Male | Inhalation | Lung | Some Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/48 0/49 1/48 1/48 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/48 0/49 3/48 0/48 COMBINED 0/48 0/49 4/48 1/48 | May Have Been Related |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Mice | B6C3F1 | Male | Inhalation | Lung | Equivocal Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 6/50 8/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 0/50 5/50 6/50 COMBINED 7/50 6/50 12/50 15/50 | Neoplastic Lesions |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Female | Inhalation | Lung | Equivocal Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/48 0/47 3/49 | Neoplastic Lesions |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 1/47 6/48, ADENOCARCINOMA 0/50 2/50 3/47 19/48, OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/47 3/48 COMBINED 0/50 4/50 5/47 27/48 | Neoplastic Lesions |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 1/35 1/65 2/50 | May Have Been Related |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50 | May Have Been Related |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/35 3/65 1/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 6/65 8/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/35 1/65 3/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 2/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50 | Neoplastic Lesions |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Female | Whole Body Exposure | Adrenal Gland Medulla | Equivocal Evidence | Equivocal Evidence | benign, malignant, or complex pheochromocytoma (1/86, 9/89, 5/87, 4/88) | May Have Been Related |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Female | Whole Body Exposure | Brain | Equivocal Evidence | Equivocal Evidence | glioma malignant (0/90, 3/90, 0/90, 0/90) | May Have Been Related |
| Yes | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Brain | Clear Evidence | Clear Evidence | glioma malignant (0/90, 0/90, 0/90, 3/90) | Neoplastic Lesions |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Female | Whole Body Exposure | Heart | Equivocal Evidence | Equivocal Evidence | schwannoma malignant (0/90, 2/90, 0/90, 2/90) | May Have Been Related |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Heart | Clear Evidence | Clear Evidence | schwannoma malignant (0/90, 2/90, 3/90, 6/90) | Neoplastic Lesions |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Liver | Clear Evidence | Equivocal Evidence | hepatocellular adenoma or carcinoma (combined) (0/90, 2/90, 4/89, 1/88) | May Have Been Related |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Pituitary Gland | Clear Evidence | Equivocal Evidence | pars distalis, adenoma (17/89, 25/90, 34/90, 13/90) | May Have Been Related |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | benign, malignant, or complex pheochromocytoma (11/88, 24/90, 28/89, 14/87) | Neoplastic Lesions |
| Yes | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Brain | Clear Evidence | Equivocal Evidence | meninges, granular cell tumor benign or malignant (1/90, 3/90, 4/90, 3/90) | May Have Been Related |
| Yes | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Brain | Clear Evidence | Clear Evidence | glioma malignant (0/90, 3/90, 3/90, 2/90) | Neoplastic Lesions |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Female | Whole Body Exposure | Heart | Equivocal Evidence | Equivocal Evidence | schwannoma malignant (0/90, 0/90, 2/90, 0/90) | May Have Been Related |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Heart | Clear Evidence | Clear Evidence | schwannoma malignant (0/90, 2/90, 1/90, 5/90) | Neoplastic Lesions |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Pancreas Islet Cell | Clear Evidence | Equivocal Evidence | adenoma or carcinoma (13/90, 27/89, 19/86, 16/85) | May Have Been Related |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Pituitary Gland | Clear Evidence | Equivocal Evidence | pars distalis, adenoma (17/89, 28/90, 26/90, 26/90) | May Have Been Related |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Prostate Gland | Clear Evidence | Equivocal Evidence | adenoma or carcinoma (2/90, 2/90, 7/90, 3/90) | May Have Been Related |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 4/50 4/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 5/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Epididymis | Clear Evidence | Equivocal Evidence | SARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 13/50 14/50 20/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 3/50 8/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 3/50 34/50 39/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Urinary Bladder | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 3/50 6/50 | Neoplastic Lesions |
| Yes | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Female | Inhalation | Brain | Some Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 0/50 1/50 0/50, GLIOMA 0/50 0/50 0/50 1/50, MEDULOBLASTOMA 0/50 0/50 0/50 1/50, MENINGEAL GRANULAR CELL TUMOR 0/50 1/50 0/50 1/50, MENINGEAL SARCOMA 0/50 1/50 0/50 1/50 | May Have Been Related |
| No | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTION) ADENOMA 0/50 2/50 2/50 6/50 (SINGLE AND STEP SECTION) ADENOMA 2/50 4/50 8/50 15/50 | Neoplastic Lesions |
| No | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Male | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 2/50 4/50 6/50 21/50 FIBROADENOMA OR CARCINOMA COMBINED 2/50 5/50 7/50 21/50 | Neoplastic Lesions |
| No | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Female | Inhalation | Mammary Gland | Some Evidence | Some Evidence | FIBROADENOMA 19/50 35/50 32/50 32/50 MULTIPLE FIBROADENOMA 7/50 12/50 19/50 17/50 | Neoplastic Lesions |
| No | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Male | Inhalation | Testis | Clear Evidence | Clear Evidence | ADENOMA 33/50 37/50 44/50 48/50 | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Brain | Positive | Positive | (ADENOCARCINOMA, NEUROBLASTOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | malignant mesothelioma 1/50 12/50 18/50 37/50 | Neoplastic Lesions |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 3/50 1/50 | May Have Been Related |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 4/50 3/50 | May Have Been Related |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 6/50 11/50 14/49 19/51 adenoma or carcinoma 6/50 11/50 14/49 20/51 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | hepatocellular adenoma 33/49 42/50 42/49 44/50 hepatocellular carcinoma 9/49 17/50 22/49 26/50 hepatoblastoma 0/49 1/50 4/49 6/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 36/49 44/50 43/49 46/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | hepatocellular carcinoma 12/50 22/50 27/49 39/51 hepatoblastoma 4/50 24/50 40/49 34/51 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 28/50 47/50 47/50 39/50 carcinoma 0/50 1/50 3/50 8/50 fibroadenoma, adenoma, or carcinoma 28/50 47/50 48/50 42/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Oral Cavity | Clear Evidence | Equivocal Evidence | (oral mucosa and tongue): squamous cell papilloma or squamous cell carcinoma 1/50 0/50 3/50 3/50 | May Have Been Related |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (subcutaneous tissue): fibroma 4/50 6/50 10/50 15/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma, keratoacanthoma, sebaceous gland adenoma, basal cell adenoma, basal cell carcinoma, or squamous cell carcinoma 9/50 7/50 15/50 21/50 | Neoplastic Lesions |